Biotechnology · Doylestown, Pennsylvania, United States
$0.74
-3.47% (-$0.03)2026-07-08
Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Net Income-$3.3M
EPS$-0.22
Market Cap$8.9M
Price Performance
Historical data including institutional events
Company Profile
O
Oren Gilad
CEO & Executive Director
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
The company is headquartered in Doylestown, Pennsylvania.
